Oncology Corporate Profile
Precision Therapeutics, a life-science company based in Pittsburgh, Pennsylvania, is committed to improving outcomes of cancer patients. As leaders in the science of individualizing cancer therapy through the use of a proprietary and unique live-tissue platform, Precision develops novel markers to help guide treatment decisions based on the biological processes of each individual_†_s cancer. Precision_†_s state of the art bioinformatics combined with the analysis of the live molecular, proteomic and genomic activity of each patient_†_s cancer offers an innovative foundation for further development and commercialization of novel predictive markers for cancer therapy.
|BioSpeciFx«•||molecular screening test||BioSpeciFx«• is a select group of clinically relevant molecular tests associated with drug response and patient prognosis.|
|ChemoFx«•||drug response marker||ChemoFx«• was designed to show chemotherapy resistance and sensitivity over a broad range of agents and tumor types, including ovarian, breast, endometrial, cervical, lung and colorectal.|
|GeneFxSM Colon||microarray-based gene signature||GeneFxSM Colon is a microarray-based gene signature developed for stage II colon cancer patients from FFPE tissue. GeneFxSM Colon is performed on a small amount of tissue, removed during surgery or a biopsy. The signature identifies patients at higher risk of recurrence within 5 years following initial surgery.|
View additional information on commercial products here »
This company does not have any pipeline products